

**THE DISTRICT OF COLUMBIA
ALCOHOLIC BEVERAGE AND CANNABIS BOARD**

In the Matter of:)	
)	
Supreme Terpene)	Case No.: 24-ULC-000012
)	License No.: N/A
Cease and Desist)	Order No.: 2024-546
)	
at premises)	
1344 U Street, N.W.)	
Washington, D.C. 20008)	

BEFORE: Donovan Anderson, Chairperson
James Short, Member
Silas Grant, Jr., Member

PARTIES: Supreme Terpene
Perry Young
1344 U Street, N.W.
Washington, D.C. 20008

U1344 LP
3029 Woodland Drive, N.W.
Washington, D.C. 20008-3544

ORDER TO CEASE AND DESIST

On July 31, 2024, the Alcoholic Beverage and Cannabis Board (Board) reviewed compelling evidence that Supreme Terpene; Perry Young; and U1344 LP engaged in a violation of Chapter 16B of Title 7 of the D.C. Official Code or permitted such illegal activity to occur. These persons and entities are hereby ordered to cease the illegal purchase, sale, exchange, delivery, or any other form of commercial transaction involving cannabis, psilocybin, and psilocyn immediately.¹

FINDINGS OF FACT

¹ The Board notes that psilocybin metabolizes into psilocyn and that both substances are present in hallucinogenic mushrooms; therefore, it is appropriate for the Order to apply to both substances. *United States Drug Enforcement Administration*, “Psilocybin,” <https://www.dea.gov/factsheets/psilocybin> (last visited July 30, 2024).

The following statements represent the Board’s findings of fact based on the evidentiary record.

1. The Board incorporates by reference the facts and evidence presented in Case Report No. 24-ULC-000012.
2. On April 25, 2024, Alcoholic Beverage and Cannabis Administration (ABCA) Supervisory Investigator (SI) Jason Peru and other District agencies inspected 1344 U Street, N.W., related to illegal cannabis activities. *Case Report No. 24-ULC-000012*, at 1. The premises were being occupied and run by a business identifying itself as Supreme Terpene owned by Perry Young. *Id.* The landlord of the premises is U1344 LP. *Id.* at 1. During the inspection, the establishment was found to have engaged in illegal cannabis activity. *Id.* In response, a warning letter was issued advising of violations regarding the illegal sale and distribution of cannabis. *Id.* at *Exhibit No. 1*.
3. On July 23, 2024, SI Peru returned to the premises for a follow up inspection. *Id.* at 2. Inside, he found that the establishment had stopped selling cannabis products containing tetrahydrocannabinol (THC) but was engaged in the sale of hallucinogenic mushrooms containing psilocybin. *Id.* For example, one photo shows products containing “Mushroom Extract.” *Id.* at *Exhibit No. 5*. The website for the business indicates that mushrooms offered by the business contain “Psilocybin” and that the store offers “magic mushrooms,” the street name for psilocybin mushroom products. *Id.* at *Exhibit Nos. 6-7*. The website further states that users can “Buy legal shrooms” from the store. *Id.* at *Exhibit No. 7*. Finally, the webpage describes the store as “one of the best mushroom and cannabis dispensaries in DC.” *Id.*
4. There is no indication that the products being displayed for sale conform with Chapter 16B and the associated regulations’ manufacturing, testing, labeling, and packaging requirements.
5. There is no indication in ABCA’s records that Supreme Terpene, has been issued any license, permit, endorsement, or other authorization from the Board that would authorize commercial cannabis operations. The Board’s records further show that Perry Young has applied for a conditional license under the name Metro Meds. *Id.* at 3.

CONCLUSIONS OF LAW

6. Under § 7-1671.12a(a) of Chapter 16B of Title 7 of the D.C. Official Code,

If the ABC Board, after investigation but before a hearing, has cause to believe that a person is violating a provision of this chapter and the violation has caused or may cause, immediate and irreparable harm to the public, the ABC Board may issue an order requiring the alleged violator to cease and desist immediately from the violation.

D.C. Code § 7-1671.12a(a).

7. Under § 7-1671.08(f),

Beginning January 31, 2024, the ABC Board may issue the following fines to an unlicensed establishment that violates § 7-1671.06(c-1) or § 7-1671.06b(e), or has not filed an accepted and pending application with the ABC Board and knowingly engages or attempts to engage in the purchase, sale, exchange, delivery, or any other form of commercial transaction involving cannabis that is not purchased, sold, exchanged, or delivered in accordance with the provisions of this chapter or § 48-904.01§.

D.C. Code § 7-1671.08(f).

8. Under § 7-1671.08(a),

Any person who manufactures, cultivates, possesses, administers, dispenses, distributes, or uses cannabis, or manufactures, possesses, distributes, or uses paraphernalia, in a manner not authorized by this chapter or the rules issued pursuant to § 7-1671.13 shall be subject to criminal prosecution and sanction under subchapter I of Chapter 11 of Title 48 [§ 48-1101 et seq.].

D.C. Code § 7-1671.08(a).

9. Under § 48-904.1(a)(1),

Except as authorized by this chapter or Chapter 16B of Title 7 [§ 7-1671.01 et seq.], it is unlawful for any person knowingly or intentionally to manufacture, distribute, or possess, with intent to manufacture or distribute, a controlled substance. Notwithstanding any provision of this chapter to the contrary, it shall be lawful, and shall not be an offense under District of Columbia law, for any person 21 years of age or older to:

- (A) Possess, use, purchase, or transport marijuana weighing 2 ounces or less; [or]
- (B) Transfer to another person 21 years of age or older, without remuneration, marijuana weighing one ounce or less

D.C. Code § 48-904.1(a)(1).

10. An “Unlicensed establishment” is

a sole proprietorship, partnership, or other business entity that:

- (A) Sells, exchanges as part of a commercial transaction, or delivers cannabis and cannabis products;
- (B) Operates at or delivers from a specific location in the District; and
- (C) Is not licensed by ABCA as a cultivation center, retailer, internet retailer, manufacturer, courier, or testing laboratory.

D.C. Code § 7-1671.01(22).

11. Under § 7-1671.12e(a),

Any building, ground, or premises where cannabis is sold, exchanged as part of a commercial transaction, delivered, or permitted to be consumed by an unlicensed establishment shall be a nuisance, except any building, ground, or premises of an applicant that filed an accepted and pending application with the Board during the 90-calendar day open application period.

D.C. Code § 7-1671.12e(a).

12. Finally, under § 7-1671.08(g)(1), it states that

. . . ABCA shall have the authority to inspect an unlicensed establishment. If, after an inspection, ABCA determines that an unlicensed establishment presents an imminent danger to the health or safety of the public, as described in paragraph (2) of this subsection, the ABC Board may summarily close and order the padlocking, by ABCA or MPD without a prior hearing, of the unlicensed establishment, and ABCA may seize all cannabis and cannabis products found at the premises.

(E) The unlicensed establishment distributes or attempts to distribute Schedule I substances, or products that contain Schedule I substances, as enumerated in section 204 of the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.04).

D.C. Code § 7-1671.08(g)(1), (E). The District of Columbia Uniform Controlled Substances Act of 1981 categorizes psilocybin and psilocyn as Schedule I narcotics. D.C. Code § 48-902.04(3)(R)-(S).

13. The Board is persuaded that Supreme Terpene; Perry Young; and U1344 LP and its agents operate unlicensed establishment or allowed an unlicensed establishment to operate and engage in the illegal sale and distribution of cannabis and mushrooms containing psilocybin, psilocyn, and similar chemicals. *Supra*, at ¶¶ 2-3. In this case, the business describes itself as a cannabis dispensary and has operated as one in the past, has applied for a medical cannabis license with ABCA, which qualifies it as an unlicensed establishment. *Supra*, at ¶ 3. The evidence further shows that the unlicensed establishment is distributing or selling products containing psilocybin, which is a Schedule I substance under the law. Therefore, the Board is satisfied that the operations observed by SI Peru constitute a violation of §§ 7-1671.08(a) and 7-1671.08(g)(1) where the business operated as unlicensed cannabis dispensary, continues to hold itself out as a cannabis dispensary, and now sells or distributes magic mushrooms. *Id.*

14. The Board notes that temporarily ceasing operations as a cannabis dispensary, even if true, does not prevent the issuance of a cease-and-desist order where past illegal operations and

the description of the business as a cannabis dispensary demonstrate that the business may likely recidivate and continue to engage in commercial cannabis activity in the future.

14. The Board further notes that the sale and distribution of illegal cannabis, psilocybin, and similar chemicals immediately threatens the health and safety of the public because unregulated product may contain inappropriate and harmful substances (e.g., pesticides, other narcotics). In addition, unlicensed businesses are at risk of selling cannabis or psilocybin to persons that should not have access to cannabis or psilocybin, such as minors or persons with serious medical conditions. Finally, such activity constitutes a nuisance under D.C. Official Code § 7-1671.13e. *See also Com. ex rel. Preate v. Danny's New Adam & Eve Bookstore*, 625 A.2d 119, 122 (1993) (It is well-settled that even a lawful business may be enjoined from operation if it is shown that, under the particular circumstance, its operation constitutes a public nuisance); *Camp v. Warrington*, 227 Ga. 674, 674, (1971) (“where it is made to appear with reasonable certainty that irreparable harm and damage will occur from the operation of an otherwise lawful business amounting to a continuing nuisance, equity will restrain the construction, maintenance or operation of such lawful business.”). Therefore, the immediate cessation of all cannabis, psilocybin, and similar activity at the premises is appropriate under § 7-1671.12a(a).

ORDER

Therefore, the Board, on this 31st day of July 2024, hereby **ORDERS** Supreme Terpene; Perry Young; and U1344 LP to immediately **CEASE AND DESIST** the illegal purchase, sale, exchange, delivery, or any other form of commercial transaction involving cannabis, psilocybin, and psilocyn.

The ABCA shall deliver a copy of this order to the Parties by hand delivery or certified mail in accordance with D.C. Official Code § 7-1671.12a(a).

District of Columbia
Alcoholic Beverage and Cannabis Board

eSigned via SeamlessDocx.com
Donovan Anderson
Key: ac430b9b59d5f0e4b730060d1dccc8

Donovan Anderson, Chairperson

eSigned via SeamlessDocx.com
James Short
Key: 547ac373f820de0ac8d1b3325d2049ec

James Short, Member



Silas Grant, Jr., Member

Pursuant to D.C. Official Code § 7-1671.12a(b)(1), “[t]he alleged violator [or violators] may, within 15 days after the service of the order, submit a written request to the ABC Board to hold a hearing on the alleged violation.” D.C. Code § 7-1671.12a(b)(1). Upon receipt of the request, the Board will provide the requestor with a “a hearing in accordance with the procedures set forth in Chapter 5 of Title 2” to challenge the cease and desist and the Board shall “issue a decision within 90 days after the hearing.” D.C. Code § 7-1671.12a(b)(2).

The requestor may also request an expedited hearing if they submit a written request “within 10 days after the service of an order” and “request [that] the ABC Board [hold] an expedited hearing on the alleged violation.” D.C. Code § 7-1671.12a(c)(1). If a timely request for an expedited hearing is made, the “Board shall conduct a hearing within 10 days after the date of receiving the request and shall deliver to the alleged violator at their last known address a written notice of the hearing by any means guaranteed to be received at least 5 days before the hearing date.” D.C. Code § 7-1671.12a(c)(2). After the expedited hearing, the Board shall issue a decision within 30 days. D.C. Code § 7-1671.12a(c)(3).

Please note that the failure to request a hearing shall result in the order being deemed final. Please further note that if you fail to comply with the order of the Board, the Board may file a petition against you with the Superior Court of the District of Columbia and seek compliance by judicial order in addition to other enforcement actions permitted by law. D.C. Code § 7-1671.12a(f)(3).

If you request a hearing, you may appear at the virtual hearing unless other instructions to appear are provided, and you and the establishment, may be represented by legal counsel. You have the right to produce witnesses and evidence on your behalf and to cross-examine witnesses. You may examine evidence produced.

All hearings are conducted in the English language. If you, any corporate officer, or any witnesses to be called are deaf, have a hearing impediment, or cannot readily understand or communicate the spoken English language, an application may be made to the Board for the appointment of a qualified interpreter.

Your failure to appear at the time and place set for the hearing, if requested, either in person or through counsel, or both, will not preclude the Board from proceeding in this matter. Should you have any questions, contact ABRA Adjudication Specialist Danette Walker at 202-442-4418.

Finally, pursuant to section 11 of the District of Columbia Administrative Procedure Act, Pub. L. 90-614, 82 Stat. 1209, D.C. Code § 2-510 (2001), and Rule 15 of the District of Columbia Court of Appeals, any party adversely affected has the right to appeal this Order by filing a petition for review, within thirty (30) days of the date of service of this Order, with the District of Columbia Court of Appeals, 430 E Street, N.W., Washington, D.C. 20001. However, the timely filing of a Motion for Reconsideration stays the time for filing a petition for review in the District of Columbia Court of Appeals until the Board rules on the motion. *See* D.C. App. Rule 15(b) (2004).